- Home
- EGY vs TECX Comparison
EGY vs TECX Comparison
Compare EGY & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- TECX
- Stock Information
- Founded
- EGY 1985
- TECX 2019
- Country
- EGY United States
- TECX United States
- Employees
- EGY N/A
- TECX N/A
- Industry
- EGY Oil & Gas Production
- TECX
- Sector
- EGY Energy
- TECX
- Exchange
- EGY Nasdaq
- TECX Nasdaq
- Market Cap
- EGY 389.8M
- TECX 334.4M
- IPO Year
- EGY N/A
- TECX 2018
- Fundamental
- Price
- EGY $3.76
- TECX $22.32
- Analyst Decision
- EGY
- TECX Strong Buy
- Analyst Count
- EGY 0
- TECX 5
- Target Price
- EGY N/A
- TECX $79.00
- AVG Volume (30 Days)
- EGY 867.2K
- TECX 250.7K
- Earning Date
- EGY 08-05-2025
- TECX 08-13-2025
- Dividend Yield
- EGY 6.65%
- TECX N/A
- EPS Growth
- EGY N/A
- TECX N/A
- EPS
- EGY 0.56
- TECX N/A
- Revenue
- EGY $489,162,000.00
- TECX N/A
- Revenue This Year
- EGY N/A
- TECX N/A
- Revenue Next Year
- EGY $24.62
- TECX N/A
- P/E Ratio
- EGY $6.76
- TECX N/A
- Revenue Growth
- EGY 3.02
- TECX N/A
- 52 Week Low
- EGY $3.00
- TECX $13.70
- 52 Week High
- EGY $7.43
- TECX $61.07
- Technical
- Relative Strength Index (RSI)
- EGY 52.69
- TECX 53.05
- Support Level
- EGY $3.53
- TECX $21.41
- Resistance Level
- EGY $3.67
- TECX $23.87
- Average True Range (ATR)
- EGY 0.13
- TECX 1.59
- MACD
- EGY -0.00
- TECX 0.07
- Stochastic Oscillator
- EGY 47.42
- TECX 50.52
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.